Aktienanalyse zu Kodiak Sciences Inc (KOD)KODKodiak Sciences Inc

Kodiak Sciences Inc. is a precommercial retina-focused biotechnology company. The Company is developing a portfolio of three late-stage clinical programs. Zenkuda (tarcocimab tedromer) has a BLA-ready profile in diabetic retinopathy, retinal vein occlusion and wet AMD, and, together with KSI-501, is being explored in the BLA-facing Phase 3 DAYBREAK wet AMD study. KSI-101 is a bispecific protein being explored in two BLA-facing Phase 3 studies in Macular Edema Secondary to Inflammation (MESI). Its Antibody Biopolymer Conjugate (ABC) Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its second investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high prevalence retinal vascular diseases to address the leading unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Kodiak Sciences Inc is a good buy right now due to its recent surge of 177% following successful drug trial results, which has driven analyst price targets up significantly, with the highest target at $145. The current price of $85.75 is well below the average target of $112, suggesting substantial upside potential. However, the company has reported negative net income figures, with a loss of $65.64 million in the latest quarter, which remains a key risk to consider.

1 analysts cover KOD: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 27.86.